Invention Grant
- Patent Title: Spiro-lactam NMDA receptor modulators and uses thereof
-
Application No.: US16321901Application Date: 2017-08-01
-
Publication No.: US10961189B2Publication Date: 2021-03-30
- Inventor: M. Amin Khan
- Applicant: Aptinyx Inc.
- Applicant Address: US IL Evanston
- Assignee: Aptinyx Inc.
- Current Assignee: Aptinyx Inc.
- Current Assignee Address: US IL Evanston
- Agency: Goodwin Procter LLP
- International Application: PCT/US2017/044813 WO 20170801
- International Announcement: WO2018/026763 WO 20180208
- Main IPC: C07D205/12
- IPC: C07D205/12 ; C07D205/08 ; A61P25/28 ; A61P25/22 ; A61P25/18 ; A61P25/24 ; A61P25/06
Abstract:
Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
Public/Granted literature
- US20190161442A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF Public/Granted day:2019-05-30
Information query
